Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cel-sci - CVM

CVM

Close Chg Chg %
0.73 -0.04 -5.60%

Closed Market

0.69

-0.04 (5.60%)

Volume: 367.95K

Last Updated:

Dec 13, 2024, 3:59 PM EDT

Trade Now

Company Overview: cel-sci - CVM

CVM Key Data

Open

$0.71

 Day Range

0.69 - 0.73

52 Week Range

0.49 - 3.23

 Market Cap

$47.22M

Shares Outstanding

63.81M

 Public Float

62.00M

Beta

0.59

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.57

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

542.18K

  

CVM Performance

1 Week
 
 47.44%
 
1 Month
 
 31.60%
 
3 Months
 
 -42.41%
 
1 Year
 
 -73.09%
 
5 Years
 
 -90.48%
 

CVM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About cel-sci - CVM

CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

CVM At a Glance

CEL-SCI Corp.
8229 Boone Boulevard
Vienna, Virginia 22182
Phone 1-703-506-9460 Revenue 0.00
Industry Biotechnology Net Income -32,194,303.00
Sector Health Technology Employees N/A
Fiscal Year-end 09 / 2024
View SEC Filings

CVM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 4.486
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.363
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.209

CVM Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

CVM Liquidity

Current Ratio 1.239
Quick Ratio 0.836
Cash Ratio 0.742

CVM Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -79.441
Return on Equity -141.894
Return on Total Capital -120.188
Return on Invested Capital -91.264

CVM Capital Structure

Total Debt to Total Equity 102.70
Total Debt to Total Capital 50.666
Total Debt to Total Assets 44.456
Long-Term Debt to Equity 87.799
Long-Term Debt to Total Capital 43.315
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cel-sci - CVM

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - 558.66K
-
Sales Growth
- - +20.73% -100.00%
-
Cost of Goods Sold (COGS) incl D&A
- 499.00K 3.88M 3.96M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.16M 499.00K 3.88M 3.96M
Depreciation
2.11M 447.00K 3.83M 3.92M
Amortization of Intangibles
53.00K 52.00K 49.00K 38.00K
COGS Growth
- - +678.23% +1.93%
-
Gross Income
- (499.00K) (3.88M) (3.96M)
Gross Income Growth
- - -678.23% -1.93%
-
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
27.38M 35.70M 32.18M 27.52M
Research & Development
17.84M 23.11M 25.36M 22.47M
Other SG&A
9.54M 12.59M 6.82M 5.05M
SGA Growth
+36.75% +30.35% -9.85% -14.49%
Other Operating Expense
- - - -
-
Unusual Expense
- 1.16M 695.05K (336.00K)
EBIT after Unusual Expense
(30.15M) (36.89M) (35.73M) (31.48M)
Non Operating Income/Expense
926.37K 1.68M 107.15K (42.81K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.04M 1.15M 1.08M 675.42K
Interest Expense Growth
-42.38% +10.95% -5.92% -37.52%
Gross Interest Expense
1.04M 1.15M 1.08M 675.42K
Interest Capitalized
- - - -
-
Pretax Income
(30.26M) (36.36M) (36.70M) (32.19M)
Pretax Income Growth
-36.69% -20.18% -0.93% +12.28%
Pretax Margin
- - - -5,415.64%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(30.26M) (36.36M) (36.70M) (32.19M)
Minority Interest Expense
- - - -
-
Net Income
(30.26M) (36.36M) (36.70M) (32.19M)
Net Income Growth
-36.69% -20.18% -0.93% +12.28%
Net Margin Growth
- - - -5,415.64%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(30.26M) (36.36M) (36.70M) (32.19M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(30.26M) (36.36M) (36.70M) (32.19M)
EPS (Basic)
-0.8231 -0.8942 -0.8721 -0.7276
EPS (Basic) Growth
-15.93% -8.64% +2.47% +16.57%
Basic Shares Outstanding
36.76M 40.66M 43.15M 44.48M
EPS (Diluted)
-0.8231 -0.8942 -0.8721 -0.7276
EPS (Diluted) Growth
-15.93% -8.64% +2.47% +16.57%
Diluted Shares Outstanding
36.76M 40.66M 43.15M 44.48M
EBITDA
(26.83M) (35.70M) (32.18M) (27.52M)
EBITDA Growth
-37.13% -33.07% +9.85% +14.49%
EBITDA Margin
- - - -4,801.69%
-

Snapshot

Average Recommendation BUY Average Target Price 8.10
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate -0.37
Last Quarter’s Earnings -0.14 Median PE on CY Estimate N/A
Year Ago Earnings -0.66 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A 1 N/A
Mean Estimate N/A N/A -0.37 N/A
High Estimates N/A N/A -0.37 N/A
Low Estimate N/A N/A -0.37 N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Cel-sci - CVM

Date Name Shares Transaction Value
May 10, 2024 Robert E. Watson Director 24,431 Open market or private purchase of non-derivative security Non-derivative transaction at $1.39 per share 33,959.09
May 9, 2024 Geert R. Kersten Chief Executive Officer; Director 1,195,309 Open market or private purchase of non-derivative security Non-derivative transaction at $1.39 per share 1,661,479.51
May 9, 2024 Patricia B. Prichep Senior Vice President 232,326 Open market or private purchase of non-derivative security Non-derivative transaction at $1.39 per share 322,933.14

Cel-Sci in the News